Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S in Dextrose 5% is a combination of electrolytes and dextrose. Dextrose provides caloric support and helps correct hypoglycemia. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) replenish fluid and electrolyte deficits, maintaining osmotic balance and acid-base homeostasis.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Intravenous replacement of fluid and electrolyte losses,Maintenance fluid therapy,Correction of metabolic acidosis (due to acetate and gluconate precursors of bicarbonate)
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion; rate and volume determined by clinical condition, fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate not exceeding 50 m L/kg/day.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable as a fixed pharmacokinetic parameter; dextrose half-life ~10 minutes (rapidly metabolized); electrolytes distribute and are cleared according to renal function. In patients with normal renal function, elimination half-life of water and electrolytes varies with hydration status and GFR.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle, releasing energy. Electrolytes are not metabolized; they are excreted renally or utilized in physiological processes.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Renal elimination of water and electrolytes; dextrose is metabolized to CO2 and water, with <1% excreted unchanged in urine. Sodium and potassium are primarily excreted renally; acetate is metabolized to bicarbonate and excreted via lungs as CO2.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
None for dextrose, sodium, potassium, chloride; acetate minimally bound (<10% to albumin).
Negligible for electrolytes and dextrose (<5%).
Dextrose: ~0.2 L/kg (total body water); sodium: ~0.6 L/kg (extracellular fluid); potassium: ~0.6 L/kg (total body water but primarily intracellular). Vd corresponds to total body water for electrolyte components.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
100% bioavailability via intravenous route.
Intravenous: 100%.
Contraindicated in patients with anuria or severe renal impairment (e GFR < 30 m L/min/1.73 m²). For mild to moderate impairment (e GFR 30-89 m L/min/1.73 m²), monitor serum potassium and renal function; adjust infusion rate based on fluid and electrolyte status.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific Child-Pugh based dose adjustment required. Use with caution in patients with severe hepatic impairment due to risk of fluid overload and electrolyte imbalances; monitor serum sodium and potassium.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Intravenous infusion; dose based on weight and clinical condition. Typical rate: 5-20 m L/kg as a single dose, not to exceed 50 m L/kg/day. Adjust based on serum electrolyte levels and fluid balance.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Use with caution due to increased risk of fluid overload, renal impairment, and electrolyte disturbances. Initiate at lower infusion rates and monitor renal function, serum electrolytes, and volume status closely.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Avoid in patients with hyperglycemia, severe renal impairment, or anuria,Monitor serum electrolytes and glucose levels during administration,Use with caution in patients with heart failure, renal disease, or those receiving corticosteroids,Risk of fluid overload and electrolyte imbalances,Do not administer unless solution is clear and container is intact
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hyperglycemia,Severe renal impairment (anuria or oliguria),Hypersensitivity to any component,Patients with elevated lactate levels or lactic acidosis
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No direct food interactions; however, dextrose content may affect blood glucose. Patients on a glucose-restricted diet should be monitored. No specific dietary restrictions required during administration.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
ISOLYTE S IN DEXTROSE 5% is an electrolyte and carbohydrate solution. No specific teratogenic effects are associated with the components at therapeutic doses. However, during pregnancy, hyperglycemia or electrolyte imbalances may harm the fetus. First trimester: No known structural teratogenicity; second and third trimesters: Potential for fetal hyperglycemia, hyperinsulinemia, and electrolyte disturbances if maternal levels are not controlled. Use only if clearly needed.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
ISOLYTE S IN DEXTROSE 5% components are endogenous and excreted into breast milk in varying amounts. Dextrose is normal milk sugar; electrolytes are present in milk. No adverse effects on nursing infants are expected at therapeutic doses. M/P ratio: Not established for the combination; individual electrolytes and dextrose have high milk/plasma ratios but are physiologic. Use with caution.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No specific dose adjustments required for pregnancy per se. However, increased plasma volume in pregnancy may alter distribution; monitor response and adjust rate based on clinical status, fluid balance, and laboratory values.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
ISOLYTE S in 5% Dextrose is a balanced electrolyte solution with 5% dextrose for maintenance fluid therapy. Monitor serum glucose closely, especially in diabetic patients. The solution provides potassium, magnesium, and phosphate; avoid in severe hyperkalemia, hypermagnesemia, or hyperphosphatemia. Contains acetate as a bicarbonate precursor; use with caution in patients with metabolic alkalosis. Do not administer with blood products due to risk of hemolysis. Incompatible with many drugs; confirm compatibility prior to Y-site administration.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This fluid contains sugar (dextrose) and electrolytes to maintain your body's balance.,Tell your healthcare provider if you have diabetes, as this may affect your blood sugar.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Notify your nurse if you experience pain, redness, or swelling at the IV site.,This solution is provided in a plastic container; do not remove from the overwrap until ready to use.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S in Dextrose 5% is a combination of electrolytes and dextrose. Dextrose provides caloric support and helps correct hypoglycemia. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) replenish fluid and electrolyte deficits, maintaining osmotic balance and acid-base homeostasis.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by clinical condition, fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate not exceeding 50 m L/kg/day.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE S IN DEXTROSE 5% is an electrolyte and carbohydrate solution. No specific teratogenic effects are associated with the components at therapeutic doses. However, during pregn. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.